« View all Healthcare Advisors
Kevin Buchi Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)
Kevin Buchi is Corporate Vice President, Global Branded Products of Teva Pharmaceuticals.
Prior to joining Teva, Kevin was CEO of Cephalon (Nasdaq: CEPH), which Teva acquired in October 2011. Kevin joined Cephalon in 1991 and held various positions, including head of business development , Chief Financial Officer and Chief Operating Officer before becoming Cephalon’s CEO in December 2010.
Kevin serves as a member of the board of directors of Mesoblast Limited, a public company traded on the Australian Stock Exchange. He graduated from Cornell University with a bachelor of arts degree in chemistry. He was a synthetic organic chemist for the Eastman Kodak Company before going on to obtain a master's degree in management from the J.L. Kellogg Graduate School of Management at Northwestern University.
He worked for a large public accounting firm before beginning his career in the pharmaceutical industry with E.I. du Pont de Nemours and Company in 1983. Mr. Buchi is a certified public accountant, and he serves on the board of directors of Celator Pharmaceuticals, Inc. located in Princeton, New Jersey.